Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy

Atsuya Takeda, Etsuo Kunieda, Toshio Ohashi, Yousuke Aoki, Yohei Oku, Tatsuji Enomoto, Koichiro Nomura, Madoka Sugiura

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Background: The primary cause of COPD and lung cancer is smoking. Thus, patients with COPD frequently have lung cancer that often is inoperable. Stereotactic body radiation therapy (SBRT) is anticipated to be the standard of care for inoperable early stage non-small cell lung cancer. The most critical toxicity following SBRT is radiation pneumonitis (RP). We analyzed predictive factors for RP following SBRT and investigated the degree and occurrence of RP in patients with severe COPD. Methods: We retrospectively evaluated 265 lung tumors treated with SBRT between 2005 and 2010 with a minimum follow-up of 6 months. Predictive factors for RP, including GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage and pack-years smoked, were evaluated by univariate and multivariate analyses. RP was graded according to the Common Terminology Criteria for Adverse Events version 3.0 scale. Results: Median follow-up was 19.2 months (range, 6.0-72.0 months). RP grades of 0, 1, 2, 3, 4, and 5 occurred in 101, 102, 49, 12, 0, and one of these patients, respectively. Multivariate analysis revealed that high normal lung volume receiving ≥20 Gy, fewer pack-years smoked, and high total dose were significant predictive factors for RP ≥grade 1, and high normal lung volume receiving 20 Gy, fewer pack-years smoked, and a history of lung resection were predictive for RP ≥grade 2. RP in patients with more severe COPD was relatively milder than in patients with normal lung function and with mild COPD. Pack-year scales were significantly correlated with GOLD stage. Conclusions: RP following SBRT in patients with severe COPD was relatively mild. Heavy smoking was the strongest negative predictor for severe RP and was correlated with severe COPD. Further follow-up and quantitative analysis of lung function might be needed to ascertain longer tolerability to SBRT.

Original languageEnglish
Pages (from-to)858-866
Number of pages9
JournalChest
Volume141
Issue number4
DOIs
Publication statusPublished - 2012 Apr

Fingerprint

Radiation Pneumonitis
Radiosurgery
Chronic Obstructive Pulmonary Disease
Radiotherapy
Lung
Lung Neoplasms
Multivariate Analysis
Smoking
Standard of Care
Terminology
Non-Small Cell Lung Carcinoma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Takeda, A., Kunieda, E., Ohashi, T., Aoki, Y., Oku, Y., Enomoto, T., ... Sugiura, M. (2012). Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest, 141(4), 858-866. https://doi.org/10.1378/chest.11-1193

Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. / Takeda, Atsuya; Kunieda, Etsuo; Ohashi, Toshio; Aoki, Yousuke; Oku, Yohei; Enomoto, Tatsuji; Nomura, Koichiro; Sugiura, Madoka.

In: Chest, Vol. 141, No. 4, 04.2012, p. 858-866.

Research output: Contribution to journalArticle

Takeda, A, Kunieda, E, Ohashi, T, Aoki, Y, Oku, Y, Enomoto, T, Nomura, K & Sugiura, M 2012, 'Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy', Chest, vol. 141, no. 4, pp. 858-866. https://doi.org/10.1378/chest.11-1193
Takeda, Atsuya ; Kunieda, Etsuo ; Ohashi, Toshio ; Aoki, Yousuke ; Oku, Yohei ; Enomoto, Tatsuji ; Nomura, Koichiro ; Sugiura, Madoka. / Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. In: Chest. 2012 ; Vol. 141, No. 4. pp. 858-866.
@article{ed2d67af4a4d4430be2b7ed0470ad45b,
title = "Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy",
abstract = "Background: The primary cause of COPD and lung cancer is smoking. Thus, patients with COPD frequently have lung cancer that often is inoperable. Stereotactic body radiation therapy (SBRT) is anticipated to be the standard of care for inoperable early stage non-small cell lung cancer. The most critical toxicity following SBRT is radiation pneumonitis (RP). We analyzed predictive factors for RP following SBRT and investigated the degree and occurrence of RP in patients with severe COPD. Methods: We retrospectively evaluated 265 lung tumors treated with SBRT between 2005 and 2010 with a minimum follow-up of 6 months. Predictive factors for RP, including GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage and pack-years smoked, were evaluated by univariate and multivariate analyses. RP was graded according to the Common Terminology Criteria for Adverse Events version 3.0 scale. Results: Median follow-up was 19.2 months (range, 6.0-72.0 months). RP grades of 0, 1, 2, 3, 4, and 5 occurred in 101, 102, 49, 12, 0, and one of these patients, respectively. Multivariate analysis revealed that high normal lung volume receiving ≥20 Gy, fewer pack-years smoked, and high total dose were significant predictive factors for RP ≥grade 1, and high normal lung volume receiving 20 Gy, fewer pack-years smoked, and a history of lung resection were predictive for RP ≥grade 2. RP in patients with more severe COPD was relatively milder than in patients with normal lung function and with mild COPD. Pack-year scales were significantly correlated with GOLD stage. Conclusions: RP following SBRT in patients with severe COPD was relatively mild. Heavy smoking was the strongest negative predictor for severe RP and was correlated with severe COPD. Further follow-up and quantitative analysis of lung function might be needed to ascertain longer tolerability to SBRT.",
author = "Atsuya Takeda and Etsuo Kunieda and Toshio Ohashi and Yousuke Aoki and Yohei Oku and Tatsuji Enomoto and Koichiro Nomura and Madoka Sugiura",
year = "2012",
month = "4",
doi = "10.1378/chest.11-1193",
language = "English",
volume = "141",
pages = "858--866",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",

}

TY - JOUR

T1 - Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy

AU - Takeda, Atsuya

AU - Kunieda, Etsuo

AU - Ohashi, Toshio

AU - Aoki, Yousuke

AU - Oku, Yohei

AU - Enomoto, Tatsuji

AU - Nomura, Koichiro

AU - Sugiura, Madoka

PY - 2012/4

Y1 - 2012/4

N2 - Background: The primary cause of COPD and lung cancer is smoking. Thus, patients with COPD frequently have lung cancer that often is inoperable. Stereotactic body radiation therapy (SBRT) is anticipated to be the standard of care for inoperable early stage non-small cell lung cancer. The most critical toxicity following SBRT is radiation pneumonitis (RP). We analyzed predictive factors for RP following SBRT and investigated the degree and occurrence of RP in patients with severe COPD. Methods: We retrospectively evaluated 265 lung tumors treated with SBRT between 2005 and 2010 with a minimum follow-up of 6 months. Predictive factors for RP, including GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage and pack-years smoked, were evaluated by univariate and multivariate analyses. RP was graded according to the Common Terminology Criteria for Adverse Events version 3.0 scale. Results: Median follow-up was 19.2 months (range, 6.0-72.0 months). RP grades of 0, 1, 2, 3, 4, and 5 occurred in 101, 102, 49, 12, 0, and one of these patients, respectively. Multivariate analysis revealed that high normal lung volume receiving ≥20 Gy, fewer pack-years smoked, and high total dose were significant predictive factors for RP ≥grade 1, and high normal lung volume receiving 20 Gy, fewer pack-years smoked, and a history of lung resection were predictive for RP ≥grade 2. RP in patients with more severe COPD was relatively milder than in patients with normal lung function and with mild COPD. Pack-year scales were significantly correlated with GOLD stage. Conclusions: RP following SBRT in patients with severe COPD was relatively mild. Heavy smoking was the strongest negative predictor for severe RP and was correlated with severe COPD. Further follow-up and quantitative analysis of lung function might be needed to ascertain longer tolerability to SBRT.

AB - Background: The primary cause of COPD and lung cancer is smoking. Thus, patients with COPD frequently have lung cancer that often is inoperable. Stereotactic body radiation therapy (SBRT) is anticipated to be the standard of care for inoperable early stage non-small cell lung cancer. The most critical toxicity following SBRT is radiation pneumonitis (RP). We analyzed predictive factors for RP following SBRT and investigated the degree and occurrence of RP in patients with severe COPD. Methods: We retrospectively evaluated 265 lung tumors treated with SBRT between 2005 and 2010 with a minimum follow-up of 6 months. Predictive factors for RP, including GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage and pack-years smoked, were evaluated by univariate and multivariate analyses. RP was graded according to the Common Terminology Criteria for Adverse Events version 3.0 scale. Results: Median follow-up was 19.2 months (range, 6.0-72.0 months). RP grades of 0, 1, 2, 3, 4, and 5 occurred in 101, 102, 49, 12, 0, and one of these patients, respectively. Multivariate analysis revealed that high normal lung volume receiving ≥20 Gy, fewer pack-years smoked, and high total dose were significant predictive factors for RP ≥grade 1, and high normal lung volume receiving 20 Gy, fewer pack-years smoked, and a history of lung resection were predictive for RP ≥grade 2. RP in patients with more severe COPD was relatively milder than in patients with normal lung function and with mild COPD. Pack-year scales were significantly correlated with GOLD stage. Conclusions: RP following SBRT in patients with severe COPD was relatively mild. Heavy smoking was the strongest negative predictor for severe RP and was correlated with severe COPD. Further follow-up and quantitative analysis of lung function might be needed to ascertain longer tolerability to SBRT.

UR - http://www.scopus.com/inward/record.url?scp=84856637280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856637280&partnerID=8YFLogxK

U2 - 10.1378/chest.11-1193

DO - 10.1378/chest.11-1193

M3 - Article

VL - 141

SP - 858

EP - 866

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -